Get the Stockscreener App
1.22
4.69%
-0.06
Pre-market:
1.20
-0.02
-1.64%
Acumen Pharmaceuticals Inc stock is traded at $1.22, with a volume of 151.46K.
It is down -4.69% in the last 24 hours and down -16.44% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$1.28
Open:
$1.28
24h Volume:
151.46K
Relative Volume:
0.52
Market Cap:
$73.30M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.0893
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
-1.61%
1M Performance:
-16.44%
6M Performance:
-53.08%
1Y Performance:
-71.95%
1-Day Range:
$1.20
$1.30
1-Week Range:
$1.19
$1.33
52-Week Range:
$1.15
$4.43
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
925-368-8508
Address
427 PARK ST., CHARLOTTESVILLE
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.22 | 73.30M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting - The Manila Times
Acumen Pharmaceuticals, Inc. to Present Research on Sabirnetug for Alzheimer's Disease at International Conferences in April 2025 - Nasdaq
Groundbreaking Alzheimer's Drug Development: Acumen Reveals Latest Research at Two Leading Conferences - StockTitan
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Sold by Rhumbline Advisers - Defense World
Alzheimer's Drug Developer Acumen Sets March Investor Presentations - StockTitan
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Cancer Immunotherapy Market Detailed In New Research Report 2025 | Gilead Sciences, Inc., Johnson & Johnson - openPR
ABOS stock touches 52-week low at $1.28 amid market challenges - Investing.com India
ABOS stock touches 52-week low at $1.28 amid market challenges By Investing.com - Investing.com South Africa
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference - Finansavisen
Acumen stock touches 52-week low at $1.54 amid market challenges - MSN
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 - MSN
Acumen Pharmaceuticals COO Barton Russell sells shares worth $4,692 - MSN
SG Americas Securities LLC Grows Stock Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $1.31 amid market challenges - MSN
ABOS stock touches 52-week low at $1.31 amid market challenges By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results - cnhinews.com
JPMorgan Chase & Co. Has $156,000 Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Barclays Cuts Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $26.00 - Defense World
ABOS stock touches 52-week low at $1.52 amid market challenges - Investing.com India
ABOS stock touches 52-week low at $1.52 amid market challenges By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals chief medical officer sells $5,118 in shares - MSN
Acumen Pharmaceuticals chief legal officer sells shares worth $5,434 - MSN
Matt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,619 Shares - MarketBeat
Acumen Pharmaceuticals CFO sells shares totaling $56,619 - MSN
Promising US Penny Stocks To Consider In January 2025 - Simply Wall St
Analysts Set Expectations for ABOS FY2025 Earnings - Defense World
Acumen Pharmaceuticals CFO sells shares totaling $56,619 By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 By Investing.com - Investing.com Canada
Brokers Offer Predictions for ABOS FY2025 Earnings - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock Holdings Lifted by Barclays PLC - Defense World
Acumen Pharmaceuticals Executives Sell Shares - TradingView
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expands By 9.1% - Defense World
Acumen stock touches 52-week low at $1.54 amid market challenges By Investing.com - Investing.com South Africa
ABOS stock touches 52-week low at $1.68 amid market challenges - Investing.com
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings - The Manila Times
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of - The Bakersfield Californian
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):